Protein phosphorylation is the most common posttranslational protein modification in eukaryotes and a fundamental mechanism for the direct or indirect control of all cellular processes. Considering the integral role that protein kinases play in the control of cellular mechanisms and signal transduction, it is not surprising that several protein kinases have been shown to be involved in spermatogenesis (1, 2) . Nevertheless, only a few kinases have been characterized, whose expression is restricted to either germ cells or to the testis. The phosphoglycerate kinase-2 and the serine/ threonine kinase MAK are predominantly expressed in spermatocytes during meiosis (3) . The serine/threonine kinase c-MOS and the kinase NEK-1 have been implicated in the control of meiosis in both spermatocytes and oocytes (4, 5) . Mouse studies demonstrate that spermiogenesis, comprising cytodifferentiation and detachment, involves a complex pattern of interaction between members of a novel family of serine/threonine kinases and as yet uncharacterized substrates (2) . Other reports describe a possible role of serine/ threonine kinases and their substrates in the progression of testicular tumors of germ cell origin (6, 7) .
Recently, Kueng et al. employed the yeast twohybrid system with testis-specific serine kinase (tssk) 1 and tssk2 cDNA as baits and a prey cDNA library from mouse testis and isolated a novel cDNA which encoded for a 65-kDa protein, interacting specifically with both tssk1 and tssk2 (2) . This protein was phosphorylated by both kinases (see GenBank Accession No. AF 025310). The expression of the interacting clone was also testis-specific and paralleled the developmental expression observed for the kinases themselves (2) . In the same study, tssk2 was found to be the orthologue of the human DGS-G gene, whose deletion is suspected to be involved in the pathogenesis of Di George and velocardiofacial syndromes (8) .
In this report we describe analysis of an area spanning approximately 100 kb of contiguous DNA sequence on human chromosome 19 (19q13.3) for the purpose of identifying new genes by the method of positional candidate cloning (9 -11) . Our approach allowed us to clone a gene, tentatively named TSKS (for testis-specific kinase substrate; GenBank Accession No. AF200923). This gene is located closed to RRAS and the human IRF3 gene. On homology analysis, the human TSKS gene was found to be similar to the Mus musculus tssk1 and tssk2 substrate (tssks) gene, described by Kueng et al. (2) . We here describe the identification of the new gene, its mapping and its localization, in relation to other genes clustering in the same region. In addition, we describe its genomic, mRNA and protein structure. We further present extensive tissue expression studies and demonstrate that, in addition to testis, which shows the highest expression, the gene is expressed at low levels in prostate, female breast, placenta, ovary, and thymus. Moreover, we examined TSKS expression in human testicular tumors and teratocarcinoma-derived cell lines and found gene downregulation in comparison to normal testicular tissue.
MATERIALS AND METHODS
Gene mapping. Large DNA sequencing data for chromosome 19 is available at the Lawrence Livermore National Laboratory (LLNL) database. We have screened approximately 100 kb of genomic sequence, encompassing a region on chromosome 19q13.3-13.4, where several cancer-associated genes are localized. These sequences were represented by 10 contigs of variable lengths. We performed a restriction analysis study of the available sequences using the "WebCutter 2" computer program and with the aid of the EcoRI restriction map of this area (also available from the LLNL), we were able to construct an almost contiguous area of genomic sequences (Fig. 1) . By using the published sequences of the RRAS oncogene and IRF3 gene, and the alignment program BLAST 2 (12), we identified the relative positions of these genes on the contiguous map.
Gene prediction analysis. For exon prediction analysis of the genomic area of interest, we used a number of different computer programs as previously described (13, 14) .
Expressed sequence tag (EST) searching. Sequence homology searching was performed using the BLASTN algorithm (12) against the human EST database (dbEST). Clones with Ͼ95% identity were obtained from the IMAGE consortium (15) through Research Genetics Inc. (Huntsville, AL) and from the Institute for Genomic Research (TIGR). Clones were propagated and purified and then sequenced from both directions with an automated sequencer, using insertflanking vector primers. All clones tested are shown in Table 1 .
Protein homology searching. Putative exons of the newly identified gene were first translated to the corresponding amino acid sequences. BLAST homology searching for the proteins encoded by the exons were performed using the BLASTP program and the GenBank databases (12) .
Structure analysis studies. Multiple alignment was performed using the Clustal X multiple alignment program (16) . Phylogenetic studies were performed using the Phylip software package (17) . Distance matrix analysis was performed using the "Neighbor-Joining/UPGMA" program and parsimony analysis was done using the "Protpars" program (18) . Hydrophobicity study was performed using the Baylor College of Medicine search launcher program. Signal peptide and transmembrane regions were predicted using the SignalP (19) and Tmpred (20) software. Protein structure analysis was performed by SAPS program (21) . Sequence analysis tools were utilized to detect the presence of possible sites of posttranslational modification on our putative protein. We used the analysis program PROSITE (22) and NetOGlyc 2.0 (23) to detect N-and O-glycosylation, as well as the presence of kinase phosphorylation motifs.
Tissue expression of TSKS. Total RNA isolated from 28 different human tissues was purchased from Clontech (Palo Alto, CA). We prepared cDNA as described below and used it for PCRs with the primers TSKS-F2 and TSKS-R1, described in Table 2 .
Expression of TSKS in testis cancer. Included in this study tissue samples from 15 patients who had undergone radical orchiectomy for testicular, tumors at the Charite University Hospital, Germany and the National University Hospital, Denmark. Patient age ranged from 23 to 60 years with a median of 36. Matched testicular tissue samples were obtained from the cancerous and non-cancerous parts of the same testis, from 10 of the patients. All patients had a histologically-confirmed diagnosis of primary testicular cancer and received no treatment before surgery. Of the 10 matched samples, 5 tumors were seminomas, 3 were categorized as embryonal carcinomas and 2 were teratocarcinomas. Other tissue samples included one Leydig cell tumor and two samples of testicular tissue containing pre-malignant carcinoma in situ tubules within morphologically normal testicular parenchyma. In addition, the expression of the TSKS gene was examined in two embryonal carcinoma cell lines derived from a human teratocarcinoma; pluripotet (NTERA-2) and nullipotent (2102Ep) (24) . The normal and tumor tissues were immediately frozen in liquid nitrogen after surgical resection and stored at Ϫ80°C until extraction. We prepared cDNA as described below and used it for PCRs with the primers TSKS-F2 and TSKS-R1 (Table 2) . Tissue cDNAs were amplified at a 1:10 dilution.
Reverse transcription-polymerase chain reaction (RT-PCR).
Total RNA was extracted from the tissues or cell lines using Trizol reagent (Gibco BRL, Gaithersburg, MD) following the manufacturer's instructions. RNA concentration was determined spectrophotometrically. Two micrograms of total RNA was reverse transcribed into first strand cDNA using the Superscript preamplification system (Gibco BRL). The final volume was 20 l. Based on the combined information obtained from the predicted genomic structure of the new gene and the EST sequences, two gene-specific primers were designed (TSKS-F2 and TSKS-R1; Table 2 ) and PCR was carried out in a reaction mixture containing 1 l of cDNA, 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl 2 , 200 M dNTPs (deoxynucleoside triphosphates), 150 ng of primers and 2.5 units of AmpliTaq Gold DNA polymerase (Roche Molecular Systems, Branchburg, NJ) on a Perkin-Elmer 9600 thermal cycler. The cycling conditions were 95°C for 15 min to activate the Taq Gold DNA polymerase, followed by 42 cycles of 94°C for 30 s, 67°C for 1 min and a final extension at 67°C for 10 min. Equal amounts of PCR products were electrophoresed on 2% agarose gels and visualized by ethidium bromide staining. The primers for RT-PCR spanned at least 2 exons to avoid contamination by genomic DNA.
Cloning and sequencing of the PCR products. To verify the identity of the PCR products, they were cloned into the pCR 2.1-TOPO vector (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. The inserts were sequenced from both directions using vector-specific primers, by an automated DNA sequencer.
Statistical analysis. Statistical analysis was performed with SAS software (SAS Institute, Cary, NC). The analyses of differences between TSKS expression in noncancerous and cancerous tissues were performed with the nonparametric McNemar test. The binomial distribution was used to compute the significance level.
RESULTS

Identification of the TSKS Gene
Exon prediction analysis of the 100-kb DNA sequence around chromosome 19q13.3 identified a novel gene with a structure reminiscent of a serine/threonine kinase substrate gene. Since our gene was found to have 73% and 81% identity at the protein and cDNA level, respectively, to the mouse tssks gene reported by Kueng et al. (2) , we assume that the newly identified TSKS gene (GenBank Accession No. AF200923) is the human homolog of the mouse tssks gene.
Cloning of the TSKS Gene
Sequence homology search of the putative exons identified by the gene prediction programs against the human EST database (dbEST) revealed five EST clones with Ͼ95% identity to the putative exons of our gene ( Table 1 ). The IMAGE clones were obtained and the inserts were sequenced from both directions. Alignment was used to compare the EST sequences and the exons predicted by the computer programs, and final selection of the exon-intron splice sites was done according to the EST sequences. Furthermore, many of the ESTs were overlapping, further ensuring the accuracy of the data. Moreover, two ESTs were found to have a poly(A) tail which was not found in the genomic sequence, verifying the 3Ј end of the gene.
To verify the accuracy of the cDNA sequence, PCRs were performed using gene-specific primers for the first and last exons of the predicted structure of the gene (TSKS-F1 and TSKS-R1; Table 2 ) with cDNA isolated from different human tissues as putative templates. The PCRs were performed under different optimization conditions using the EST clones as positive controls. A positive band of the expected size was isolated from testis cDNA and fully sequenced. Its sequence was aligned by BLAST against the genomic sequence to further define and confirm the exon/intron boundaries. The genomic and cDNA sequence of the gene is now deposited in GenBank (Accession No. AF200923).
Mapping and Chromosomal Localization of the TSKS Gene
Alignment of the sequences of TSKS and other known genes that we found to be located within the 100-kb area of interest, on chromosome 19q13.3, enabled us to precisely localize these genes and determine the distances between them, as shown in Fig. 1 . The TSKS gene maps between two known genes, namely RRAS and the human ␣-Adaptin A gene, and transcribes in the opposite direction. Human ␣-Adaptin A is 3.7 kb more telomeric to TSKS while RRAS is 5.5 kb more centromeric to it. The IRF3 gene maps in the same region, and transcribes in the same BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS direction with RRAS. The distance between IRF3 and RRAS was calculated to be 19.5 kb (Fig. 1) .
Structural Characterization of the TSKS Gene and Its Protein Product
As shown in 
Protein Analysis
The predicted protein-coding region of the gene is formed of 1779 bp (including the stop codon), encoding a deduced amino acid polypeptide of 592 residues, with a predicted molecular mass of 65.1 kDa and a theoretical isoelectric point of 5.7.
A hydrophobicity study of the TSKS protein shows a hydrophobic area in the N-terminal region of the protein (Fig. 3) ; thus, a presumed signal peptide is present. By software analysis, a possible 19-amino-acid signal peptide is predicted with a cleavage site at the carboxyl end of Gly 19 . TSKS protein is predicted to have no transmembrane region, in agreement with the mouse homolog protein. The mouse tssks protein was found to be phosphorylated on serine residues by the tssk1 and tssk2 kinase enzymes (2). We predicted 22 serine and 9 threonine potential phosphorylation sites, as well as 3 serine and 2 threonine glycosylation sites (Fig. 4) .
Expression of the TSKS Gene in Human Tissues
We have assessed by RT-PCR the tissues that express the TSKS gene. The experiments were performed at various dilutions of the cDNA to obtain preliminary information about the relative levels of expression. RT-PCR for actin was used as a positive control and RT-PCR for PSA cDNA was used as another positive control with tissue restricted specificity. Positive ESTs for TSKS were also used as controls. The PSA gene was found to be highly expressed in the prostate, as expected, and to a much lower extent in mammary, salivary glands, thyroid gland, and trachea, as also reported recently (27, 28) .
The tissue expression of TSKS is summarized in Fig.  5 . This kinase substrate is highly expressed in the testis. Much lower levels of expression are seen in prostate, placenta, fetal liver, thymus, and mammary gland. No expression was seen for the other tested tissues. To verify the RT-PCR specificity, representative PCR products were cloned and sequenced.
TSKS Expression in Testicular Cancer
Expression of the TSKS gene in testicular cancer, at the mRNA level, was examined by RT-PCR, with the BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS tent embryonal carcinoma-cell lines exhibited very low levels of expression (Fig. 6) .
To examine the expression of the TSKS gene in benign and malignant tissues we analyzed 10 pairs of testicular tissues (cancer/normal) and the results are summarized in Fig. 7 . Nine of 10 patients had significantly higher TSKS expression in the non-cancerous tissue and only one had about the same levels of expression in both tissues. Expression of the TSKS gene was not detectable in tumor from 7 of 10 patients. Analysis by the McNemar test indicated that the changes between non-cancer vs cancer tissues are statistically significant (P ϭ 0.004). Because of the small number of cases, binomial distribution was used to compute the significance level.
DISCUSSION
Using linear genomic sequences of considerable length, gene prediction programs and the available EST database, we were able to identify a new gene, tentatively named TSKS (for testis specific kinase substrate). This gene is composed of 11 exons and ten introns and is likely to be the human homolog of the mouse testis specific serine kinase substrate gene (tssks) (2) . This is based on the considerable homologies at the amino acid and nucleotide sequence level, and the tissue-restricted expression to the testis. The predicted protein-coding region of the gene is 1779 bp and encodes for a 592-amino-acid polypeptide with a predicted molecular weight of 65.1 kDa. The 3Ј end of the gene was verified by the presence of a poly A tail in the sequenced ESTs which was not found in the genomic sequence. The start codon was identified by the presence of a consensus Kozak sequence. The exon-intron splice junctions were identified by comparing the genomic sequence with the EST or cDNA sequence obtained by RT-PCR and were further verified by the full conservation of the consensus splice sequences (25) .
The human TSKS gene is located on chromosome 19q13.3, close to RRAS and IRF3. In this study, we also identified the location of the IRF3 gene in relation to the RRAS gene. The distance between IRF3 and RRAS was calculated to be 19.5 kb and both of them transcribe in the same direction (Fig. 1) . The connection of the RAS genes to human malignancy is well-known (29) . IRF3 is a member of a growing family of transcription factors. It is becoming increasingly apparent that IRF3 plays a pivotal role in the cell's response to viral infection. Phosphorylation and activation of IRF3 in response to stimuli other than viral infection may result in transcription of genes, in addition to the early inflammatory genes (30, 31) . Activation of IRF3 by growth factors can lead to a negative feedback control of cell growth (31).
Kueng et al. recently found that mouse tssk2 is the likely ortholog of the human DGS-G gene (2) . The DGS-G gene has been characterized as one of eleven putative transcription units encoded in the minimal DiGeorge critical region of 250 kb, located on the proximal arm of human chromosome 22, whose deletion is suspected to be involved in the pathogenesis of the DiGeorge and velocardiofacial syndromes. Both syndromes represent developmental disorders associated with a spectrum of malformations including hypoplasia of the thymus and parathyroid glands, cardiovascular anomalies, and mild craniofacial dysmorphia. In light of the fact that the mouse tssks protein, a substrate for mouse tssk2, is homologous to human TSKS, we can speculate that the TSKS protein may be a substrate of the DGS-G protein. This proposal merits further investigation. Our results indicate that the expression of TSKS is down-regulated in testicular cancer. TSKS expression was very low or undetectable in a Ledig cell tumor and in germ-cell tumors, including seminoma, teratocarcinoma, embryonal carcinoma as well as in a embryonal carcinoma cell lines. The high TSKS expression in tissue with carcinoma in situ is most probably due to the presence of normal seminiferous tubules with preserved spermatogenesis. Such tubules were seen in other fragments of tissue isolated from the same patients.
The neighboring RRAS and IRF3 genes are also involved in tumorigenesis pathways and progression (29 -32) . The observation that TSKS is located in the region of chromosome 19 that is often deleted in gliomas, suggests that it should be further investigated as a putative tumor suppressor (30, 31) . The presence of many GC clusters in the promoter area (data not shown) of the TSKS suggests that transcription of this gene, similar to that of other tumor suppressor genes, may be inactivated through methylation.
The mouse homolog of TSSK, tssks, was found with immunohistochemistry to be expressed in the cytoplasm of spermatids located in the luminal cell layer of the seminiferous tubules (2) . Consistent with these findings, we found that TSKS, aside from a putative 19-amino-acid signal peptide, does not have any predicted transmembrane regions. Interestingly, tssks was expressed in the cytoplasm of spermatids undergoing nuclear condensation as well as in apparently unnuclear cytoplasmic remnants, which may later give rise to the smaller residual bodies. Mouse tssks protein is not involved in the process of chromatin condensation, but rather, participates in the reconstruction of the sperm cytoplasm and reflects the different stages of sperm maturation in the individual tubular section. The human homolog may play similar roles but this proposal needs further investigation when antibodies have become available. Nevertheless, our observation of the high expression of the human TSKS gene in normal tissue and morphologically normal tissue adjacent to overt tumors (with or without carcinoma in situ) is consistent with the putative localization of the transcript to the haploid germ cells, most probably spermatids.
In conclusion, we have cloned a new gene, TSKS, which appears to be the human homolog of the mouse tssks gene. This gene appears to be a substrate for testis-specific kinases and is specifically expressed in the testis. We speculate that this gene is involved in sperm formation and may play a role in the pathogenesis of DiGeorge and velocardiofacial syndromes. Due to it tissue specificity, and differential expression in testicular cancers, TSKS protein may find clinical applications in testicular pathologies and may be a target for future gene therapy treatments.
